Skip to content

Home Versus Hospital Care in Glucose Monitoring of Gestational Diabetes and Mild Gestational Hyperglycemia

A Prospective Randomized Trial of Home Versus Hospital Care in Glucose Monitoring of Gestational Diabetes and Mild Gestational Hyperglycemia

Status
Completed
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01441518
Enrollment
80
Registered
2011-09-27
Start date
2010-05-31
Completion date
2013-11-30
Last updated
2015-07-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gestational Diabetes Mellitus, Mild Gestational Hyperglycemia, Pregestational Diabetes Mellitus

Brief summary

Pregnancies complicated by diabetes and mild gestational hyperglycemia are associated with increased perinatal and maternal complications. The most serious maternal complication is the risk of developing type 2 diabetes after 10-12 years of the delivery. Perinatal complications include fetal macrosomia with consequent increased risk of obstetrical trauma and hypoxia/asphyxia, high rates of cesarean section, respiratory distress syndrome, and metabolic disorders at birth. Regardless of the diagnosis of diabetes and mild gestational hyperglycemia, the perinatal outcome is directly related to maternal metabolic control. For the tight control of blood glucose, pregnant women are treated as home care (outpatient) or hospital care. Objective: To evaluate the cost-effectiveness and safety of home versus hospital care of gestational diabetes and mild gestational hyperglycemia.

Interventions

Home care, sometimes called ambulatory care or outpatient, was defined as the blood-glucose self-monitored by the pregnant women at home. This project will provide glucometers to all those who are randomized to home care. The women will receive training for glucose control in pre-defined days, with the glucometer to obtain the mean glucose. According to blood-glucose levels in glycemic profile, insulin dose will be maintained or altered both in gestational diabetes as in mild gestational hyperglycemia .

OTHERHospital care

Hospital care, sometimes called acute care, was defined as control of maternal diabetes made at hospitals by admission to hospital. The blood-glucose and metabolic control are done in gestational diabetes and mild gestational hyperglycemia treated conventionally. The hospitalized patients will have their glycemic control done in the hospital. . According to blood-glucose levels in glycemic profile , insulin dose will be maintained or altered both in gestational diabetes as in mild gestational hyperglycemia. All the women of the study will be accompanied by a team of obstetricians specializing in high-risk pregnancies; residents; dietitians; nurses and neonatologists.

Sponsors

UPECLIN HC FM Botucatu Unesp
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 45 Years
Healthy volunteers
No

Inclusion criteria

* Patients who were diagnosed with gestational, pre gestational diabetes mellitus or mild gestational hyperglycemia. Patients should have one of the four criteria as following: * Patients with positive screening for GDM presenting a TTG of 75 g and one of the values below: * fasting glucose ≥ 92; * 1h ≥ 180; or * 2h ≥ 153 will be considered gestational diabetes mellitus (GDM) and these patients will be enrolled to a run-in phase consisting of diet and exercise during 15 days. If the patients still present an abnormal glycemic profile instead of the previous treatment with diet and exercise they will be enrolled in the study and randomized to either home or hospital care; or * Patients with pre gestational diabetes mellitus type 1 or 2; or * Patients with positive screening for GDM and presenting normal TTG of 75 g and abnormal glycemic profile, fasting ≥ 85 mg k/l 10 h to 18h post prandial ≥ 130 mg k/ ( Rudge et al,1990). * Normal TTG and an abnormal glycemic profile will be considered as mild gestational hyperglycemia * Patient provided written informed consent.

Exclusion criteria

* Twin pregnancy diagnosed until the date of randomization or; * Fetal malformation diagnosed until the date of randomization.

Design outcomes

Primary

MeasureTime frame
Maternal mortality and morbidity ratesparticipants will be followed regarding maternal and perinatal mortality and morbidity rates up to six weeks postnatal
Perinatal mortality and morbidity ratesparticipants will be followed regarding maternal and perinatal mortality and morbidity rates up to six weeks postnatal

Secondary

MeasureTime frame
Infants repeated hospitalizationsinfants will be followed for repeated hospitalizations up to six weeks postnatal
Infants acute care visitsinfants will be followed for acute care visits up to six weeks postnatal
Length of stay for deliveryparticipants will be followed for length of stay for delivery, an expected average of 9 months
Maternal prenatal and postpartum acute care visitsparticipants will be followed for maternal prenatal and postpartum acute care visits up to six weeks postnatal
Birth weight (classified as appropriate for gestational age = AIG, small for gestational age =SGA and large for gestational age = LGA)birth weight will be assessed for an expected average of 9 months from the time of randomization
Incidence of premature infantsparticipants will be followed regarding incidence of premature infants up to six weeks postnatal
Postpartum repeated hospitalizationparticipants will be followed for Postpartum repeated hospitalization up to six weeks postnatal
Glucose controlparticipants will be followed for glucose control up to six weeks postnatal
Costscosts will be assessed for an expected average of 9 months from the time of randomization
Biophysical profile testsparticipants will be followed for biophysical profile tests up to six weeks postnatal
Maternal hospitalizations for any causes (home care) and prolonged hospitalization (hospital care)participants will be followed for maternal hospitalizations for any causes and prolonged hospitalization up to six weeks postnatal

Countries

Brazil

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026